Abstract CN3
Background
Chemotherapy induced nausea and vomiting adversely affect the children's quality of life and disturb their compliance with treatment. Therefore, it is important to effectively manage nausea and vomiting and to involve children in this process. This study aimed to develop an interactive mobile application and to examine the effect of this application on the management of chemotherapy induced nausea and vomiting in children.
Methods
Randomized controlled, prospective study was conducted in a university hospital between October 2019-January 2021 with 57 children aged 8-18 years old (control=31; experiment=26) who took chemotherapy and their mothers. In the study, a mobile application named "5inD" was developed, which includes various distraction methods to reduce nausea and vomiting. The experimental group used this mobile application. Data were collected by ‘Information Form’ and ‘Adapted Rhodes Index of Nausea and Vomiting for Pediatrics (ARINV)’. The nausea and vomiting of the children were evaluated twice a day by the children and their mothers for seven days starting from the first day of chemotherapy. Data were analyzed by descriptive analysis, Mann Whitney U test, Wilcoxon test, Spearman correlation coefficient and chi-square test using IBM SPSS for Windows version 24.0 program.
Results
The distribution of descriptive children’s characteristics according to groups is homogeneous (p>0.05). It was a statistically significant difference between the mean scores of the ARINV reported for children and mothers among groups (p<0.05). The mean ARINV scores reported by mothers and children were similar (p>0.05). The age of children, the number of chemotherapy cycles, and chemotherapy’s emetogenic risk group did not affect the mean scale scores reported by mothers and children (p<0.05).
Conclusions
It was found that the frequency of nausea-vomiting, the amount of vomiting and disturbance reported by mothers and children in experimental group was less, so 5inD was effective in reducing chemotherapy induced nausea and vomiting in children. Therefore, 5inD should be used in pediatric oncology clinics in the management of nausea and vomiting.
Clinical trial identification
NCT04693832.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Trakya University Scientific Research Projects Unit.
Disclosure
R. Semerci: Financial Interests, Institutional, Funding: Trakya University. M. Akgün Kostak: Financial Interests, Institutional, Funding: Trakya University.